Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK ; volume:36 ; number:8 ; day:25 ; month:5 ; year:2018 ; pages:1015-1027 ; date:8.2018
PharmacoEconomics ; 36, Heft 8 (25.5.2018), 1015-1027, 8.2018
- Urheber
-
Emery, Paul
- Beteiligte Personen und Organisationen
-
Keep, Marjolijn Van
Beard, Steve
Graham, Chris
Miles, LaStella
Jugl, Steffen Marc
Gunda, Praveen
Halliday, Anna
Marzo-Ortega, Helena
SpringerLink (Online service)
- DOI
-
10.1007/s40273-018-0675-9
- URN
-
urn:nbn:de:101:1-2018090221041305341208
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Emery, Paul
- Keep, Marjolijn Van
- Beard, Steve
- Graham, Chris
- Miles, LaStella
- Jugl, Steffen Marc
- Gunda, Praveen
- Halliday, Anna
- Marzo-Ortega, Helena
- SpringerLink (Online service)
Ähnliche Objekte (12)
Secukinumab: A Review in Ankylosing Spondylitis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective
Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
Andersson lesion in ankylosing spondylitis
Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison
Normative values for the bath ankylosing spondylitis functional index in the general population compared with ankylosing spondylitis patients in Morocco
Efficacy and NSAID-sparing effect of secukinumab 150 mg in ankylosing spondylitis : results from phase IV ASTRUM study
Surgical treatment of ankylosing spondylitis deformity
Ankylosierende Spondylitis: Secukinumab lindert Fatigue schnell und anhaltend
Secukinumab: A Review in Ankylosing Spondylitis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective
Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
Andersson lesion in ankylosing spondylitis
Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison
Normative values for the bath ankylosing spondylitis functional index in the general population compared with ankylosing spondylitis patients in Morocco
Efficacy and NSAID-sparing effect of secukinumab 150 mg in ankylosing spondylitis : results from phase IV ASTRUM study
Surgical treatment of ankylosing spondylitis deformity
Ankylosierende Spondylitis: Secukinumab lindert Fatigue schnell und anhaltend
Secukinumab: A Review in Ankylosing Spondylitis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective
Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
Andersson lesion in ankylosing spondylitis
Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison
Normative values for the bath ankylosing spondylitis functional index in the general population compared with ankylosing spondylitis patients in Morocco
Efficacy and NSAID-sparing effect of secukinumab 150 mg in ankylosing spondylitis : results from phase IV ASTRUM study
Surgical treatment of ankylosing spondylitis deformity